Delos Capital ’s Post

#ICYMI: A panelist of experts discussed how real world data (RWD) is transforming precision oncology during our recent webinar, "Searching in a More Complete Haystack: Using Real World Data to Guide Precision Oncology Drug Development." Read the summary and key takeaways: https://buff.ly/3ZfjiVW. Watch the full webinar recording: https://buff.ly/3VeOnaL #RWE #RWD #Oncology #DrugDevelopment #PrecisionOncology #RealWorldEvidence #RealWorldData #Biomarket #Cancer

It's not too late to register for this week's webinar, Oncology 2050: Have We Been Thinking About the Management of Cancer in the Right Way? Join us as we dive into the future of oncology, redefining treatment strategies, advancing AI, and more. Register at https://lnkd.in/gRc_wcPh Hear from our panel of experts, including Axel Hoos, Peter Sandor, EVP, Astellas Pharma US, and Lumanity's Jeff Bockman, Viraj Parekh, and Dennis Chang. #Oncology #Cancer #CancerProgress #CancerTreatment #AIinCancerTreatment

#BreastCancerAwarenessMonth – A CCTG trial spotlight: MAC27 is a breast clinical trial with the goal of finding out if the combination of a new drug and a commonly used drug is better than the commonly used drug alone at preventing this type of breast cancer from returning. #SolvingCancerTogether #ClinicalTrials https://buff.ly/3U2gbP5

Keya Watkins shares her key takeaways from the 2024 Society for Immunotherapy of Cancer (SITC) conference. While there has been a lot of progress in recent years, there is much more work (and many successes) ahead. Read about the presentations she attended and where the convergence of technology and science will help us to develop new oncology treatments. https://hubs.li/Q02Z-M8y0 #SITC2024 #InnovationsTechnology #ScienceAdvancements #OncologyBreakthroughs #ConnectWithCatalyst

Unravel the complexities of cancer treatment with patient-level insights. Gain speedy access to robust, real-world data from 350,000 patient cases and over 5,300 specialists annually with IQVIA’s Oncology Dynamics. Learn more: https://bit.ly/3DcSE8A

Tune in as Daejin Abidoye joins a #FierceBiotech panel to share his insights on antibody-drug conjugates (#ADCs) and how we’re working to advance novel #cancer treatment options for patients. Learn more about our work in oncology: https://bit.ly/3NtOhbc

Join your peers for this must-attend #webinar reviewing different types of linkers and payloads used in antibody-drug conjugates, as well as key methodologies involved in developing robust bioassays for #ADCs. Register today to gain access to the live event and on-demand recording. #medicinalchemistry #biotechnology #ADC #cellbasedassay #drugdiscovery #biology #chemistry #CDMO

Always great to talk to Jeff about the vision and journey of CancerLinQ®, founded by American Society of Clinical Oncology (ASCO) and now an initiative of ConcertAI - Robert Miller https://lnkd.in/dDfy7nP3 #oncodaily #oncology #cancer #technology #data #AI #precisiononcology #RWD #CancerResearch #oncologydata

Just In: The Breast Cancer Drug Market In 2023, sales of leading breast cancer drugs reached approximately $28 billion. The primary agents driving this growth were CDK4/6 inhibitors and HER2-targeted therapies. For a deeper dive into emerging treatments & market trends, explore this latest analysis 👉 https://lnkd.in/dU-sKFqe @NatRevDrugDisc #bcsm #trendings

Scancell Holdings sets ambitious roadmap for the next 18 months @scancellpharma #AIM #OTC #SCLP #SCNLF. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has rolled out its roadmap for the next 18 months, which builds on the significant clinical progress made to date. An early milestone comes from the release of full cohort data for SCIB1 and iSCIB1+ (for melanoma) in late 2024 and early 2025. The cancer immunotherapy specialist also plans to launch a phase II/III registration trial for SCIB1 or iSCIB1+ in 2025. In the first stage of the phase II study of SCIB1, 11 out of 13 patients achieved at least a partial response, exceeding the 70% overall response rate the... http://ow.ly/HivJ105JH51